You're contacting media contact of this press release

Title: Giftify, Inc. Announces Smart Savings Solution for Popular GLP-1 Diabetes and Weight Loss Medications

New York, United States, 21st Feb 2025 - Giftify, Inc. (NASDAQ:GIFT) (the "Company"), the owner and operator of CardCash.com and Restaurant.com, and a leader in the incentives and rewards industry, today announced that CardCash.com is offering consumers smart saving solutions for high-cost GLP-1 weight loss prescription medications like Ozempic (semaglutide) from Novo Nordisk and Zepbound (tirzepatide) from Eli Lilly.CardCash.com, Giftify's secondary gift card exchange platform, provides consumers with an innovative approach to reduce rising out-of-pocket expenses for increasingly popular GLP-1 medications. The strategy leverages discounted pharmacy gift cards from major retailers including CVS and Walgreens.This program aligns with current national efforts to address healthcare affordability challenges. By providing practical tools to reduce prescription costs, CardCash.com is contributing to the ongoing public dialogue around making essential medications more accessible for all Americans, particularly as policymakers continue to explore comprehensive solutions to rising healthcare expenses.Consumer feedback validates the financial impact of this approach. “As one Trustpilot reviewer, Corey Polk, shared, ‘I had significant savings on my Walgreens cards. I used it to buy Ozempic, and now I save about $30 a month.’ This is exactly what we aim for at CardCash — helping consumers find financial relief where they need it most,” said Carol Rosenblum, Marketing Manager at CardCash.com.The platform's strategy creates a multi-layered savings opportunity for medication purchasers. Users can combine CardCash's discounted gift cards with manufacturer savings programs and prescription discount services like GoodRx and SingleCare. Additional cost reductions can be achieved through p...

This press release is issued by King Newswire